Detalhe da pesquisa
1.
Pre-therapy PET-based voxel-wise dosimetry prediction by characterizing intra-organ heterogeneity in PSMA-directed radiopharmaceutical theranostics.
Eur J Nucl Med Mol Imaging
; 2024 May 09.
Artigo
Inglês
| MEDLINE | ID: mdl-38724653
2.
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer.
Radiology
; 308(1): e222148, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37432081
3.
Comparative Analysis of Morphological and Functional Effects of 225Ac- and 177Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands.
Int J Mol Sci
; 24(23)2023 Nov 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38069166
4.
Whole-body uptake classification and prostate cancer staging in 68Ga-PSMA-11 PET/CT using dual-tracer learning.
Eur J Nucl Med Mol Imaging
; 49(2): 517-526, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34232350
5.
Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy.
Eur J Nucl Med Mol Imaging
; 49(12): 4064-4072, 2022 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-35771265
6.
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
Eur J Nucl Med Mol Imaging
; 49(12): 4271-4281, 2022 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-35767071
7.
The added value of PSMA PET/MR radiomics for prostate cancer staging.
Eur J Nucl Med Mol Imaging
; 49(2): 527-538, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34255130
8.
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
Lancet Oncol
; 22(8): 1115-1125, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34246328
9.
Almost 10 years of PET/MR attenuation correction: the effect on lesion quantification with PSMA: clinical evaluation on 200 prostate cancer patients.
Eur J Nucl Med Mol Imaging
; 48(2): 543-553, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32725538
10.
Deep neural network for automatic characterization of lesions on 68Ga-PSMA-11 PET/CT.
Eur J Nucl Med Mol Imaging
; 47(3): 603-613, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31813050
11.
68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study.
J Urol
; 202(6): 1174-1181, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31233369
12.
68Ga-FAPI-46 and 18F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors.
Eur J Nucl Med Mol Imaging
; 48(11): 3736-3737, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33914106
14.
Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging
; 46(10): 2212-2213, 2019 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-31273434
15.
Treatment Response Imaging in Prostate Cancer.
PET Clin
; 2024 Apr 25.
Artigo
Inglês
| MEDLINE | ID: mdl-38670877
16.
Prostate-specific Membrane Antigen: Interpretation Criteria, Standardized Reporting, and the Use of Machine Learning.
PET Clin
; 2024 May 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38705743
17.
RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med
; 2024 Apr 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38637143
18.
Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers.
J Nucl Med
; 65(3): 438-445, 2024 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38238041
19.
Prognostic Performance of RECIP 1.0 Based on [18F]PSMA-1007 PET in Prostate Cancer Patients Treated with [177Lu]Lu-PSMA I&T.
J Nucl Med
; 65(4): 560-565, 2024 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38453363
20.
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial.
Eur Urol Oncol
; 2024 Apr 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38584037